NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Therapeutics entered a binding term sheet with a global pharma company for PrimeC, its ALS treatment, including substantial upfront payment, Phase 3 study funding, milestone payments, and double-digit royalties on net sales. The deal is subject to a definitive agreement expected in Q1 2025.